2 assets in Paranasal Sinus Neoplasm

Therapeutic assets addressing Paranasal Sinus Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Docetaxel Paranasal Sinus Neoplasm	National Cancer Institute (NCI)	P1/2	CCC (48)
SX682 Paranasal Sinus Neoplasm	National Cancer Institute (NCI)	P1/2	CCC (48)